Last reviewed · How we verify
NCT02994030: BioDuchenne
Biomarker for Duchenne Muscular Dystrophy
trial in Increased Lordosis/Scoliosis in 103 participants. Completed in 11 March 2022.
11 March 2022
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 103 |
| Start date | 20 August 2018 |
| Primary completion | 11 March 2022 |
| Estimated completion | 11 March 2022 |
| Sites | 12 locations across Georgia, Pakistan, Sri Lanka, Romania, Lebanon, Albania, Egypt, India |
Conditions studied
- Increased Lordosis/Scoliosis — all drugs for Increased Lordosis/Scoliosis →
- Hyporeflexia — all drugs for Hyporeflexia →
- Duchenne Muscular Dystrophy — all drugs for Duchenne Muscular Dystrophy →
- Red-Green Color Blindness — all drugs for Red-Green Color Blindness →
Sponsor
CENTOGENE GmbH Rostock
Who can join
Adults 2 Months to 50, any sex, with Increased Lordosis/Scoliosis or Hyporeflexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
International, multicenter, observational, longitudinal study to identify biomarker/s for Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02994030
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
- NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02994030 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 24 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02994030.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing